8-K - BriaCell Therapeutics Corp. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

BriaCell Therapeutics Corp. disclosed BriaPro Therapeutics Corp.'s unaudited condensed interim financial statements for the six months ended January 31, 2026, showing increased operating losses and minimal cash, furnished under Item 7.01 as Regulation FD disclosure.

Key Takeaways

1BriaPro reported operating loss of $497,943 for six months ended January 31, 2026 vs. $210,035 prior year.

2Comprehensive loss of $472,231 for the period, with basic and diluted EPS of $(0.011).

3Cash and equivalents remained at $1, with total assets of $176,890 and shareholders' deficit of $1,618,141.

4Due to related parties increased to $1,606,112 from $1,121,053 at July 31, 2025.

5On February 18, 2026, entered purchase agreement to acquire BriaCell's sCD80 license, closed March 30, 2026.

6Jamieson Bondarenko appointed BriaPro board Chairman upon sCD80 transaction closing.

Current Report Details

Event Type

Regulation Fd

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Excha

Regulation Fd

9.01

Condensed interim financial statements and Exhibits** **EXHIBIT INDEX** | Exhibit No. | | | |---|---|---| | 99.1 | | BriaPro Therapeutics Corp. Unaudited Conden

Exhibits Only

Source Document

Results of Operations

Six months ended January 31, 2026

Metric	Value	Prior Period
Operating loss	$-497.9K	$-210.0K
Total operating loss and comprehensive loss	$-472.2K	$-233.2K
Basic and diluted weighted average loss per share	$-0.01	$-0.01

Exhibits (3)

8-K

99.1

EX-99.1

99.2

EX-99.2